Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18758358 | GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATE | June 2024 | October 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18758344 | GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATE | June 2024 | October 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18755445 | METHODS OF TREATING FIBROSIS | June 2024 | November 2024 | Allow | 5 | 1 | 0 | No | No |
| 18670637 | EFFECTIVE TREATMENT OF DEPRESSION IN PATIENTS HAVING IMPAIRED LEARNING AND/OR MEMORY OR CERTAIN EEG CHARACTERISTICS WITH A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | May 2024 | September 2024 | Allow | 4 | 1 | 0 | No | No |
| 18654926 | Testosterone Dodecanoate Compositions and Methods | May 2024 | February 2025 | Allow | 9 | 2 | 1 | No | No |
| 18643034 | ESKETAMINE FOR THE TREATMENT OF DEPRESSION | April 2024 | February 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18621541 | METHOD OF INCREASING LIFESPAN IN MAMMALS | March 2024 | October 2024 | Allow | 7 | 1 | 0 | No | No |
| 18616636 | LPXC INHIBITORS AND USES THEREOF | March 2024 | October 2024 | Allow | 7 | 1 | 0 | No | No |
| 18596341 | COMPOSITIONS AND METHODS FOR TREATING POLYCYTHEMIA | March 2024 | December 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18592795 | Compositions and Methods for Improving the Solubility of Erectile Dysfunction Therapeutics | March 2024 | July 2024 | Allow | 5 | 1 | 0 | No | No |
| 18437405 | Oral (17-�)-3-Oxoandrost-4-EN-17-YL Tridecanoate Therapy | February 2024 | July 2024 | Allow | 5 | 1 | 0 | No | No |
| 18399141 | PHARMACOLOGICALLY ACTIVE LIPOSOMAL COMPOSITION COMPRISING QUERCETIN AND ZINC | December 2023 | July 2024 | Allow | 7 | 1 | 0 | No | No |
| 18395225 | TIZANIDINE LIQUID PREPARATION AND USE THEREOF | December 2023 | May 2024 | Allow | 5 | 2 | 0 | No | No |
| 18537085 | 4,5-BIS(4-METHOXYPHENYL)-1-HEXYL-2-PHENYL-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUND | December 2023 | May 2024 | Allow | 5 | 2 | 0 | No | No |
| 18526935 | COMPOUNDS AND METHODS FOR MODULATING HER2 | December 2023 | June 2024 | Allow | 6 | 1 | 0 | No | No |
| 18505349 | 2-AMINO-4-(4-BROMOPHENYL)-6-ETHOXYPYRIDINE-3,5-DICARBONITRILE AS AN ANTIBACTERIAL COMPOUND | November 2023 | April 2024 | Allow | 5 | 1 | 0 | No | No |
| 18387748 | 4,5-BIS(4-BROMO-PHENYL)-1-HEXYL-2-(2-METHOXYPHENYL)-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUND | November 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18494155 | METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS | October 2023 | January 2024 | Allow | 3 | 1 | 0 | No | No |
| 18494754 | NOVEL METHODS | October 2023 | July 2024 | Allow | 9 | 2 | 0 | No | No |
| 18379383 | 2-ALKOXY[4,3:6,3-TERPYRIDINE]-3-CARBONITRILES AS ANTIMICROBIAL COMPOUNDS | October 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18453085 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | August 2023 | January 2024 | Allow | 5 | 1 | 0 | No | No |
| 18217864 | NON-RACEMIC BETA-HYDROXYBUTYRATE COMPOUNDS AND COMPOSITIONS ENRICHED WITH THE R-ENANTIOMER AND METHODS OF USE | July 2023 | May 2024 | Allow | 10 | 1 | 0 | No | No |
| 18337552 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | June 2023 | January 2024 | Allow | 7 | 1 | 0 | No | No |
| 18203378 | EXPERIMENTAL MODEL USING PAZOPANIB-INDUCED CARDIOTOXICITY | May 2023 | January 2024 | Allow | 7 | 2 | 0 | No | No |
| 18325548 | METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS | May 2023 | January 2024 | Allow | 7 | 1 | 0 | No | No |
| 18197100 | Reduced Dose Metaxalone Formulations | May 2023 | November 2023 | Allow | 6 | 2 | 0 | No | No |
| 18313267 | METHODS OF TREATING HEART FAILURE WITH CARDIAC SARCOMERE ACTIVATORS | May 2023 | January 2024 | Allow | 9 | 1 | 0 | No | No |
| 18300668 | TREATMENT FOR PRIMARY BILIARY CHOLANGITIS | April 2023 | October 2023 | Allow | 6 | 1 | 0 | No | No |
| 18296532 | METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS | April 2023 | September 2023 | Allow | 5 | 1 | 0 | No | No |
| 18247412 | PREVENTION OF KIDNEY INJURY INDUCED BY HEMOLYTIC REACTION | March 2023 | October 2024 | Allow | 19 | 1 | 0 | No | No |
| 18185045 | NON-LINEAR DOSING OF MIRDAMETINIB | March 2023 | July 2023 | Allow | 4 | 1 | 0 | No | No |
| 18118272 | HIGH YIELD EXTRACTION METHOD FOR AND PRODUCTS OF CORYDALIS PLANTS | March 2023 | September 2023 | Allow | 6 | 1 | 1 | No | No |
| 18118256 | HIGH YIELD EXTRACTION METHOD FOR AND PRODUCTS OF RHODIOLA PLANTS | March 2023 | September 2023 | Allow | 6 | 1 | 1 | No | No |
| 18176850 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | March 2023 | August 2023 | Allow | 5 | 1 | 1 | No | No |
| 18176848 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | March 2023 | August 2023 | Allow | 5 | 1 | 1 | No | No |
| 18175605 | METHODS OF USING RHO KINASE INHIBITORS TO TREAT ALZHEIMER'S DISEASE | February 2023 | August 2023 | Allow | 5 | 1 | 0 | No | No |
| 18174063 | 18-MC FOR TREATMENT OF SUBSTANCE USE DISORDERS | February 2023 | January 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18147921 | SOLID FORMS OF A DUAL RAF/MEK INHIBITOR | December 2022 | November 2023 | Allow | 11 | 1 | 0 | No | No |
| 18083326 | COMPOSITIONS AND METHODS FOR DELAYING THE INCIDENCE OF LABOR | December 2022 | February 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18062107 | COMMON COLD SYMPTOM RELIEVING AGENT | December 2022 | February 2024 | Allow | 14 | 2 | 0 | No | No |
| 17992275 | HYDROGEL FORMULATIONS AND METHODS AND DEVICES FOR FOCAL ADMINISTRATION OF THE SAME | November 2022 | October 2023 | Allow | 11 | 1 | 1 | Yes | No |
| 17981092 | CONTINUOUS ADMINISTRATION OF PHARMACEUTICAL COMPOSITION FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | November 2022 | November 2024 | Allow | 25 | 1 | 0 | No | No |
| 18051228 | 4-PIVALOYLOXY-N-METHYLTRYPTAMMONIUM CHLORIDE | October 2022 | January 2024 | Allow | 14 | 2 | 0 | No | No |
| 17977969 | COMPOSITIONS FOR PREVENTION AND TREATMENT OF SYMPTOMS ASSOCIATED WITH ALCOHOL CONSUMPTION | October 2022 | February 2025 | Abandon | 27 | 1 | 0 | No | No |
| 17976407 | PRODRUGS OF L-BHDU AND METHODS OF TREATING VIRAL INFECTIONS | October 2022 | November 2023 | Allow | 13 | 1 | 0 | No | No |
| 17976066 | USE OF DIHYDROBERBERINE OR ITS DERIVATIVES TO ENHANCE MUSCLE FUNCTION | October 2022 | December 2023 | Allow | 13 | 1 | 0 | Yes | No |
| 18049983 | TOPICAL SUBSTANCE FOR VAGINAL USE | October 2022 | October 2024 | Allow | 23 | 1 | 0 | No | No |
| 18049589 | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | October 2022 | August 2023 | Allow | 10 | 2 | 0 | No | No |
| 17968264 | Compositions and Methods for Treating Neurological Disorders | October 2022 | October 2024 | Allow | 24 | 1 | 0 | No | No |
| 18045919 | TREATING SPONDYLOARTHRITIC AND PSORIATIC CONDITIONS WITH UPADACITINIB | October 2022 | January 2025 | Abandon | 28 | 1 | 0 | No | No |
| 17938872 | METHODS TO CONTROL INFECTION USING NEW GENERATION SMALL MOLECULE GROWTH INHIBITORS | October 2022 | August 2024 | Allow | 22 | 2 | 0 | No | No |
| 17954864 | Pharmacological Prophylactics Against Stress-Induced Affective Disorders In Females | September 2022 | October 2024 | Allow | 25 | 1 | 0 | No | No |
| 17953768 | COMBINATION THERAPIES COMPRISING TARGETED THERAPEUTICS | September 2022 | December 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17906575 | CRYSTALLINE NORPSILOCIN COMPOUNDS | September 2022 | February 2024 | Allow | 17 | 2 | 0 | No | No |
| 17944751 | SUCCINATE PRODRUG, COMPOSITIONS CONTAINING THE SUCCINATE PRODRUG AND USES THEREOF | September 2022 | July 2024 | Allow | 23 | 1 | 0 | No | No |
| 17941061 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | September 2022 | July 2024 | Abandon | 22 | 1 | 1 | No | No |
| 17890342 | D-Serine Inhibits Neuroinflammation Due To A Brain Injury | August 2022 | August 2024 | Allow | 24 | 1 | 0 | No | No |
| 17880949 | TREATMENT FOR PRIMARY BILIARY CHOLANGITIS | August 2022 | August 2024 | Allow | 25 | 1 | 0 | No | No |
| 17816071 | Compositions comprising Quinone and/or Quinol and methods of preparations and use thereof | July 2022 | October 2024 | Allow | 26 | 1 | 0 | Yes | No |
| 17872749 | AMINO ACID COMPOSITIONS AND METHODS FOR THE TREATMENT OF POST-ACUTE SEQUELAE OF COVID-19 | July 2022 | April 2023 | Allow | 9 | 1 | 1 | No | No |
| 17813158 | USE OF SENICAPOC FOR TREATMENT OF STROKE | July 2022 | August 2024 | Allow | 25 | 1 | 0 | No | No |
| 17863902 | METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS | July 2022 | August 2024 | Allow | 26 | 1 | 0 | No | No |
| 17855945 | VIDOFLUDIMUS FOR USE IN THE TREATMENT OR PREVENTION OF VIRAL DISEASES | July 2022 | July 2024 | Allow | 25 | 1 | 0 | No | No |
| 17843028 | METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS | June 2022 | June 2024 | Allow | 24 | 1 | 0 | No | No |
| 17842073 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | June 2022 | October 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17837740 | GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATE | June 2022 | November 2024 | Allow | 29 | 2 | 0 | No | Yes |
| 17834297 | Food Safety Method | June 2022 | August 2024 | Allow | 26 | 1 | 0 | No | No |
| 17804126 | Treatment of Affective Disorders | May 2022 | December 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17745011 | TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY | May 2022 | April 2024 | Allow | 23 | 2 | 0 | No | No |
| 17741879 | METHOD OF TREATMENT BASED ON REDUCED MONOAMINE OXIDASE A ACTIVITY | May 2022 | October 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17735368 | METHODS AND COMPOSITIONS FOR TREATING INFECTION AND INFLAMMATION WITH SELENOCYANATE | May 2022 | March 2024 | Allow | 23 | 1 | 0 | No | No |
| 17735798 | METHOD OF TREATING FIBROSIS | May 2022 | December 2022 | Allow | 7 | 1 | 0 | No | No |
| 17735061 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | May 2022 | August 2022 | Allow | 4 | 1 | 0 | No | No |
| 17729780 | HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | April 2022 | August 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17725970 | DEOXYCHOLIC ACID INJECTIONS FOR SNORING AND OBSTRUCTIVE SLEEP APNEA | April 2022 | September 2023 | Allow | 17 | 1 | 0 | No | No |
| 17724125 | COMPOSITIONS AND METHODS FOR INHIBITING Mpro and PLpro PROTEASE ACTIVITY AND FOR PREVENTING AND TREATING SARS-CoV-2 INFECTION | April 2022 | August 2023 | Allow | 16 | 2 | 0 | No | No |
| 17722325 | REVERSING BALDNESS THROUGH CANNABINOID RECEPTOR ACTIVATION | April 2022 | November 2024 | Allow | 31 | 2 | 1 | No | No |
| 17722244 | SULFASALAZINE SALTS, PRODUCTION PROCESSES AND USES | April 2022 | August 2024 | Allow | 28 | 1 | 1 | No | No |
| 17658852 | UNIT ORAL DOSE COMPOSITIONS COMPOSED OF IBUPROFEN AND FAMOTIDINE FOR THE TREATMENT OF ACUTE PAIN AND THE REDUCTION OF THE SEVERITY AND/OR RISK OF HEARTBURN | April 2022 | March 2024 | Allow | 24 | 1 | 0 | No | No |
| 17719066 | Methods of Treating Retinal Vasculopathies | April 2022 | November 2023 | Allow | 20 | 1 | 0 | No | No |
| 17717486 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | April 2022 | September 2022 | Allow | 5 | 1 | 0 | No | No |
| 17658494 | METHOD OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS | April 2022 | October 2024 | Allow | 30 | 2 | 0 | No | No |
| 17714238 | METHODS OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME USING COLCHICINE | April 2022 | August 2023 | Allow | 17 | 1 | 0 | No | No |
| 17713880 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | April 2022 | March 2024 | Allow | 23 | 1 | 1 | No | No |
| 17711548 | CANNABIS EXTRACTS AND METHODS OF PREPARING AND USING SAME | April 2022 | September 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17711277 | ESKETAMINE FOR THE TREATMENT OF DEPRESSION | April 2022 | January 2023 | Allow | 10 | 1 | 0 | No | No |
| 17657515 | 9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | March 2022 | March 2024 | Allow | 24 | 1 | 0 | No | No |
| 17700547 | Pharmaceutical composition for inhibiting the infectivity of lipid bilayer viruses, treating associated diseases and their complications | March 2022 | October 2023 | Allow | 19 | 1 | 0 | No | No |
| 17698189 | METHOD FOR TREATMENT OF PARKINSON'S DISEASE | March 2022 | July 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17655015 | NOVEL NUTRACEUTICAL COMPOSITIONS | March 2022 | November 2023 | Allow | 20 | 2 | 0 | Yes | No |
| 17696204 | COMPOSITIONS AND METHODS FOR STIMULATING VENTILATORY AND/OR RESPIRATORY DRIVE | March 2022 | February 2024 | Allow | 23 | 2 | 1 | No | No |
| 17686738 | FOSPROPOFOL METHODS AND COMPOSITIONS | March 2022 | November 2022 | Allow | 8 | 2 | 0 | No | No |
| 17685636 | STABLE READY-TO-USE PARENTERAL COMPOSITIONS OF FOSAPREPITANT | March 2022 | August 2022 | Allow | 6 | 1 | 0 | No | No |
| 17684306 | COMBINATION THERAPY | March 2022 | July 2024 | Allow | 29 | 1 | 0 | No | No |
| 17682448 | COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND STRENGTH, TREATING SKIN, REDUCING WEAR AND DEGRADATION FROM AGING AND EXPOSURE AND IMPROVING RECOVERY FROM STRESS SUCH AS EXERCISE AND TRAUMA | February 2022 | September 2024 | Allow | 30 | 1 | 0 | No | No |
| 17679439 | Tryptamine Prodrugs | February 2022 | November 2024 | Abandon | 33 | 2 | 0 | No | No |
| 17636608 | CONJUGATES AND CONJUGATES FOR USE IN PREVENTING OR TREATING OF BRAIN DAMAGE AND NEURODEGENERATIVE DISEASES | February 2022 | February 2023 | Abandon | 12 | 0 | 1 | No | No |
| 17672731 | Treatment of mitochondrial diseases | February 2022 | March 2024 | Allow | 24 | 1 | 0 | No | No |
| 17587827 | HIGH YIELD EXTRACTION METHOD FOR AND PRODUCTS OF CORYDALIS PLANTS | January 2022 | October 2022 | Allow | 9 | 1 | 1 | No | No |
| 17587771 | HIGH YIELD EXTRACTION METHOD FOR AND PRODUCTS OF RHODIOLA PLANTS | January 2022 | October 2022 | Allow | 9 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SHIAO, REI TSANG.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 26.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SHIAO, REI TSANG works in Art Unit 1629 and has examined 686 patent applications in our dataset. With an allowance rate of 81.2%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 22 months.
Examiner SHIAO, REI TSANG's allowance rate of 81.2% places them in the 45% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by SHIAO, REI TSANG receive 1.39 office actions before reaching final disposition. This places the examiner in the 30% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by SHIAO, REI TSANG is 22 months. This places the examiner in the 79% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a -13.9% benefit to allowance rate for applications examined by SHIAO, REI TSANG. This interview benefit is in the 1% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 36.9% of applications are subsequently allowed. This success rate is in the 81% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 82.6% of cases where such amendments are filed. This entry rate is in the 96% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 95.0% of appeals filed. This is in the 83% percentile among all examiners. Of these withdrawals, 73.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 34.5% are granted (fully or in part). This grant rate is in the 29% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 1.6% of allowed cases (in the 74% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.